This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 21425053
Submitted by lobbyist on: September 15, 2014 04:17:34 PM
Accepted by Registrar on: September 16, 2014 11:15:25 AM
Lobbyist Information
| Laws, Candice |
| 633 - 6th Ave Suite 1000 | |
|
calgary, AB, T2P 2Y5
|
403-269-1624 |
| Canada |
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbyist Firm Information
| Global Public Affairs |
| 633 - 6th Ave Suite 1000 | |
|
calgary, AB, T2P 2Y5
|
403-269-1624 |
| Canada |
Client Information
| Shire Canada Inc. |
| Shire Canada Inc. "Shire Canada" and Shire Human Genetic Therapies (Canada) Inc. "Shire Human Genetic Therapies (Canada)" are wholly owned subsidiaries of Shire Plc, a global specialty bio pharmaceutical company that works closely with specialist physicians to develop and market medicines that improve the quality of life for patients, their families and caregivers. Shire focuses on attention deficit hyperactivity disorder (ADHD), human genetic therapies, hereditary angioedema, as well as gastrointestinal and renal diseases. |
| 2250, Alfred-Nobel Blvd., Suit | |
|
St-Laurent, QC, H4S 2C9
|
204-479-3277 |
| Canada |
Relevant Affiliates
Type:
| Business Name | Mailing Address | Contact Information |
|---|---|---|
| Shire Pharmaceuticals Limited |
Hampshire International Business Park Chineham, Basingstoke
Hampshire, Ireland |
Phone: |
Government or Government Agency Funding
The organization does not receive any funding from a government or government agency.
Other Controlling or Directing Interests
The organization has no other controlling or directing interests.
Undertaking Information
| September 5, 2014 | |
| September 15, 2015 |
There are no other individuals engaged to lobby on this undertaking.
Lobbying Activities
Health
Arranging meeting between an individual and a public office holder
Introduction of Shire's therapies including: human genetic therapies, hereditary angioedema, as well as gastrointestinal and renal disease and specifically attention deficit hyperactivity disorder (ADHD).
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Staff of Minister | Minister of Health | September 15, 2014 |